DDInter1066 DDInter624
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Lidocaine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Efavirenz
Lidocaine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Lidocaine {u} (Compound) causes {v} (Side Effect) Vision blurred
Vision blurred {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Lidocaine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) regulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Lidocaine {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nelfinavir
Nelfinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Lidocaine {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nelfinavir
Nelfinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nevirapine
Nevirapine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nevirapine
Nevirapine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Efavirenz
Lidocaine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Efavirenz (Compound)
Lidocaine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Efavirenz (Compound)
Lidocaine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Efavirenz (Compound)
Lidocaine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) regulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Lidocaine may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Lidocaine may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Nevirapine and Nevirapine (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Nevirapine and Nevirapine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Efavirenz (Compound)